Neutral lipid storage disease with myopathy (NLSDM) is a rare but severe genetic disorder characterized by excessive lipid accumulation in tissues including skin, bone marrow, heart, liver, and muscles. Clinically, NLSDM patients present with severe dilated cardiomyopathy, skeletal muscle myopathy, and insulin resistance. 1 NLSDM is caused by a defect in the PNPLA2 gene encoding the enzyme adipose triglyceride lipase (ATGL), 2 which catalyzes the breakdown of triglycerides in multiple tissues and is the rate-limiting step of lipolysis. Although heterozygous carriers and homozygous patients both present with similar clinical symptoms, the severity of these symptoms in homozygous patients is more dramatic, leading to premature death attributed to dilated cardiomyopathy in some patients. 1, 2 To date, the only available treatment is strict dietary guidelines and is focused on treating the comorbidities rather than targeting the primary defect.
To investigate cardiac lipotoxicity in NLSDM, ATGL-deficient mice have been investigated. Just like NLSDM patients, ATGLdeficient mice are also characterized by excessive lipid storage in skeletal muscle, liver, and heart, and they develop cardiomyopathy at a young age, resulting in premature death. 3 Interestingly, we reported recently that a lack of ATGL resulted in a diminished cardiac peroxisome proliferator-activated receptor (PPAR) activity and mitochondrial function, suggesting that lipolysis-derived fatty acids or fatty acid byproducts serve as transcriptional activators of PPARs. 4 Subsequently, pharmacological treatment of ATGL-deficient mice with PPAR agonists completely reversed the mitochondrial defects, restored cardiac function, and prevented premature death. These promising findings inspired us to investigate whether PPAR agonist treatment in patients and carriers of a PNPLA2 gene defect could also have beneficial effects.
Although NSLDM is a very rare disease, we had the opportunity to study 2 sisters with PNPLA2 gene mutations. Patient 1 is a 37-year-old woman with a body mass index of 21.4 kg/m 2 . During childhood, patient 1 developed hearing loss and progressive proximal muscle weakness. Histological analysis revealed increased lipid accumulation in skeletal muscle and Jordan bodies in white blood cells. At the age of 34 years, she developed a diffuse hypokinesia of the left and right ventricles of the heart with a decreased ejection fraction. Because of a nonsustained ventricular tachycardia, she received an implantable cardioverter defibrillator. The diagnosis of NLSDM in this patient was made after a DNA sequence analysis, showing 2 different mutations in both PNPLA2 alleles, causing a compound heterozygous mutation: a deletion causing a frame-shift at amino acid position 270 and a missense mutation 584C→T, which changes proline to leucine at amino acid 195, as described previously. 1 Patient 2 is the 39-year-old sister of patient 1, with a body mass index of 27.7 kg/m 2 . She is a heterozygous carrier of the frame-shift at amino acid position 270 mutation and presents with symptoms, albeit milder than her sister. Clinically, the patient is characterized by mild myopathy, reduced exercise tolerance, a history of chronic otitis media, and 1 episode of meningitis. A muscle biopsy and the presence of Jordan bodies confirmed neutral lipid storage.
We treated both patients with bezafibrate (Bezalip, Actavis, 400 mg daily) for 28 weeks. Four body mass index-and agematched female control subjects served as a patient-specific reference group but did not receive any treatment.
As expected, fibrate treatment resulted in a decrease in circulating triglyceride levels (-20% in patient 1 and -65% in patient 2; Table) . Meanwhile, no changes in other circulating plasma parameters were observed. In both patients, metabolic clearance rate, a measure of whole-body insulin sensitivity measured using a hyperinsulinemic euglycemic clamp, 5 was lower compared with controls but slightly improved after 12 weeks of bezafibrate treatment (Table) . Furthermore, both patients showed a marked increase in metabolic flexibility (change in respiratory quotient from fasted to insulin-stimulated condition) after bezafibrate treatment (△ respiratory quotient from 0.03 to 0.16 in patient 1 and 0.09 to 0.17 in patient 2 versus control △ respiratory quotient of 0.12). Whole-body fat oxidation, measured in the fasted state, slightly increased after 12 and 28 weeks of treatment in both patients, whereas fasting glucose oxidation rates declined over this intervention period, normalizing to values found in controls ( Figure A) . Ex vivo fatty acid oxidative capacity was determined in muscle biopsies. Unfortunately, biopsy yield in patient 2 was too small to perform this assay at week 0. In both patients, ex vivo fatty acid oxidation markedly improved and normalized toward control values ( Figure B) , with no marked changes in ex vivo glucose oxidation (data not shown). Furthermore, ex vivo mitochondrial function (determined in permeabilized muscle fibers) upon the addition of octanoyl-carnitine showed similar improvements as the palmitate oxidation assay (data not shown). These data indicate that, as in ATGL-deficient mice, fatty acid oxidation in these patients improved on fibrate treatment.
Most importantly, skeletal muscle lipid content, measured in muscle biopsies using oil red O staining, strongly decreased in both patients on treatment, although it remained elevated compared with controls ( Figure C) . Lipid accumulation in cardiac muscle and liver in patient 2, measured with 1 H-magnetic resonance spectroscopy, 6 also seemed to decrease over the 28-week intervention period ( Figure D) . Because of the presence of an implantable cardioverter defibrillator, these magnetic resonance spectroscopy measurements could not be performed in patient 1.
Despite a marked decrease in tissue lipid accumulation and an improvement in oxidative metabolism, no major changes were (yet) found in clinical parameters. Handgrip strength was low in NLSDM patients and did not change on bezafibrate treatment in either subject (data not presented). However, both patients did show an improvement in a leg extension test, a measure of leg muscle strength ( Figure E ). Although this did seem to consistently improve, the values for both patients remained low compared with age, body mass index, and sex-matched controls (Figure E, dotted lines) .
Cardiac function at baseline was impaired in patient 1 and normal in patient 2 (Table) . Patient 1, who is known to have frequent arrhythmias before treatment, only had 1 episode with a nonsustained ventricular tachycardia during the intervention period, as registered by the implantable cardioverter defibrillator. Still, neither the ultrasound nor the ECG could detect marked changes in cardiac function in both patients after 28 weeks of treatment (Table) .
Consistent with the findings in mice lacking ATGL, 4 bezafibrate treatment resulted in a marked lowering of cardiac and muscle fat content and an increase in fat oxidative capacity. In healthy subjects, fibrates were shown not to affect ectopic lipid content, 7, 8 suggesting that fibrates may reduce the extreme lipid accumulation that characterizes NLSDM by upregulating and normalizing oxidative metabolism. Haemmerle et al 4 showed recently that the lack of ATGL prevents liberation of fatty acids (or fatty acid intermediates) for PPAR signaling from the lipid droplet, hence resulting in an impaired fat oxidative capacity. As a consequence, oxidation of circulatory fatty acids taken up in muscle, liver, and heart is compromised, and these fatty acids will be more readily directed to storage. By providing synthetic PPAR agonists to ATGL-deficient mice, fat oxidative capacity could be increased, ectopic fat storage was blunted, and cardiac dysfunction was completely restored. The results presented here indicate that, in humans with compromised ATGL activity, PPAR treatment results in similar improvements in fat oxidation and tissue lipid storage, as in ATGL-deficient mice. However, unlike ATGL-deficient mice, the improvements in lipid accumulation and oxidative metabolism observed in our patients did not (yet) result in pronounced clinical changes. Leg muscle strength did improve but was not paralleled by a decrease/normalization of creatine kinase levels or a change in handgrip strength. Furthermore, cardiac function seemed unaltered. Whether the lack of clinical changes are attributed to the relative short duration of the treatment or the fact that treatment could only be started in patients who are in a later stage of the disease (note that ATGLdeficient mice were treated from early age onward) cannot be deduced from the present study and needs further investigation.
In conclusion, our results suggest that, similar to mice lacking ATGL, NLSDM patients may also benefit from bezafibrate treatment with respect to lipid accumulation and fat oxidative capacity. However, 28 weeks of bezafibrate treatment did not result in clinical changes in these patients. Longer studies are needed to investigate whether these improvements can also translate into clinical improvements in these patients. Changes in plasma values and cardiac ultrasound (US). Results are presented for controls and both patients before and after 12 and 28 wk of treatment with Bezafibrate. Plasma values are determined after an overnight fast and during a hyperinsulinemic euglycemic clamp. Ultrasound results are presented for 2-dimensional imaging. BMI indicates body mass index; CK, creatine kinase; FS, fractional shortening; LVEF, left ventricular ejection fraction; LV mass, left ventricular mass calculated according to the American Society of Echocardiography convention; MCR, metabolic clearance rate of glucose; and Rel WT, relative wall thickness.
